$1.80
0.137.78%
Last update: Nov 11, 4:14 PM
enGene Therapeutics Inc
ENGNNASDAQ
enGene Therapeutics fell 81.1% from $8.82 to $1.67, behind the S&P 500's +9.8%. Its worst day was May 7 (−80.6%), and its low came May 12 at $1.44.
Story events cover the past 12 months · Times ET
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.73 missed the $-0.57 estimate on $0.00 revenue.
+5.1% · S&P 500 +0.5%
enGene Therapeutics closed at its highest level of the year, 38.0% above where the year started.
+14.4% · S&P 500 0.0%
EPS of $-0.44 beat the $-0.56 estimate on $0.00 revenue.
−18.8% · S&P 500 +0.9%
enGene Therapeutics closed at its lowest level of the year, 83.7% below where the year started.
−3.4% · S&P 500 −0.2%
EPS of $-0.43 beat the $-0.47 estimate on $0.00 revenue.
+9.3% · S&P 500 +1.8%
EPS of $-0.47 missed the $-0.44 estimate on $0.00 revenue.
+5.5% · S&P 500 −0.5%
Where it ended: a close of $1.67 on Nov 10, 2026. Up next: Q4 2026 earnings on Dec 21, 2026 (EPS est. $-0.46).
Nothing in the past 12 months.
All ENGN dividend history
